Are you Dr. Karwal?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 51 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
200 Hawkins Dr
Iowa City, IA 52242Phone+1 319-353-7900Fax+1 319-353-8377
Summary
- Dr. Mark Karwal, MD is an oncologist in Iowa City, Iowa. He is currently licensed to practice medicine in Iowa. He is affiliated with University of Iowa Hospitals and Clinics and Jefferson County Health Center.
Education & Training
- University of Iowa Hospitals and ClinicsFellowship, Hematology and Medical Oncology, 1991 - 1994
- University of Iowa (Des Moines)Residency, Internal Medicine, 1984 - 1987
- University of Iowa Roy J. and Lucille A. Carver College of MedicineClass of 1984
Certifications & Licensure
- IA State Medical License 1984 - 2025
- American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
Clinical Trials
- Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer Start of enrollment: 2013 Jan 01
- A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein Start of enrollment: 2015 Jul 20
Publications & Presentations
PubMed
- 41 citationsPembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial.Gontran Verset, Ivan Borbath, Mark Karwal, Chris Verslype, Hans Van Vlierberghe
Clinical Cancer Research. 2022-06-13 - 6 citationsA Pilot Study of Preoperative Vandetanib on Markers of Proliferation and Apoptosis in Breast Cancer.Philip M Spanheimer, Amani Bashir, Allison W. Lorenzen, Anna C. Beck, Junlin Liao
American Journal of Clinical Oncology. 2021-09-01 - 4 citationsRamucirumab in patients with previously treated advanced hepatocellular carcinoma: Impact of liver disease aetiology.Peter R. Galle, Masatoshi Kudo, Josep M. Llovet, Richard S. Finn, Mark Karwal
Liver International. 2021-06-26